Prognostic value of urokinase plasminogen activator system in non‑small cell lung cancer: A systematic review and meta‑analysis

  • Authors:
    • Jia‑Ju Lu
    • Hong Guo
    • Bo Gao
    • Yun Zhang
    • Qing‑Ling Lin
    • Jiang Shi
    • Jing‑Jing Liu
    • Jian Liu
  • View Affiliations

  • Published online on: November 3, 2017     https://doi.org/10.3892/mco.2017.1484
  • Pages:127-132
Metrics: HTML 0 views | PDF 0 views
0

Abstract

Current relevant research suggests there are significant differences between the expression of the urokinase plasminogen activator (uPA) system in cancer tissues and in normal tissues. However, the potential effectiveness of the uPA system as a prognostic biomarker of non‑small cell lung cancer (NSCLC) remains unclear. In the present study, a systematic review and meta‑analysis were performed to evaluate the relevance of the uPA system in the prognosis of patients with NSCLC. Using the PubMed, EMBASE, Web of Science and Cochrane Library databases, data from relevant academic journal articles were extracted and subjected to analysis. Associations between expression profiles pertaining to the uPA system and the overall survival (OS) of patients with NSCLC were analyzed. The study incorporated data from 11 independent journal articles and these reports included a total of 937 patients with NSCLC. The meta‑analysis results revealed that increased expression of urokinase plasminogen activator (uPA) and PA inhibitor type 1 (PAI‑1) exhibited no significant association with poor OS [hazard ratio (HR)‑uPA=1.07 (0.87‑1.31), P=0.53; HR‑PAI‑1=1.02 (0.63‑1.65), P=0.94]. Similarly, reduced expression of PAI type 2 (PAI‑2) did not significantly correlate with poor OS [HR‑PAI‑2=1.58 (0.64‑3.90); P=0.32]. Notably, however, a significant association was observed between increased expression levels of uPA receptor (uPAR) and poor OS for NSCLC [HR‑uPAR=1.50 (1.04‑2.15); P=0.03]. Therefore, the expression of uPAR in the uPA system of patients with NSCLC could be used as a novel clinical biomarker to evaluate the prognosis of NSCLC. The utilization of this biomarker may provide a platform for the further development of targeted drugs for the treatment of NSCLC.

Related Articles

Journal Cover

January 2018
Volume 8 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Lu, J., Guo, H., Gao, B., Zhang, Y., Lin, Q., Shi, J. ... Liu, J. (2018). Prognostic value of urokinase plasminogen activator system in non‑small cell lung cancer: A systematic review and meta‑analysis. Molecular and Clinical Oncology, 8, 127-132. https://doi.org/10.3892/mco.2017.1484
MLA
Lu, J., Guo, H., Gao, B., Zhang, Y., Lin, Q., Shi, J., Liu, J., Liu, J."Prognostic value of urokinase plasminogen activator system in non‑small cell lung cancer: A systematic review and meta‑analysis". Molecular and Clinical Oncology 8.1 (2018): 127-132.
Chicago
Lu, J., Guo, H., Gao, B., Zhang, Y., Lin, Q., Shi, J., Liu, J., Liu, J."Prognostic value of urokinase plasminogen activator system in non‑small cell lung cancer: A systematic review and meta‑analysis". Molecular and Clinical Oncology 8, no. 1 (2018): 127-132. https://doi.org/10.3892/mco.2017.1484